Semaglutide vs Tesamorelin

Side-by-side comparison of Semaglutide, Tesamorelin — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute Semaglutide Semaglutide (GLP-1 Receptor Agonist) Weight Loss Tesamorelin Tesamorelin (GHRH Analogue) Growth Hormone
Basics
Molecular type GLP-1 Receptor AgonistGHRH Analogue
Amino acids 3144
Molecular weight 4,113.6 Da5,135.8 Da
Half-life ~7 days~30 min
Route(s) Subcutaneous injection, Oral (Rybelsus)Subcutaneous
Mechanism & Research
Primary mechanism Semaglutide binds and activates GLP-1 receptors throughout the body with high affinity. In the pancreas, it stimulates glucose-dependent insulin secretion and suppresses glucagon release. These effects are glucose-depend… Tesamorelin binds and activates pituitary GHRH receptors with the full-length 44-amino-acid native GHRH sequence, producing more complete pituitary signalling than the 29-amino-acid fragments (sermorelin, CJC-1295). Its …
Research status FDA Approved FDA Approved
Evidence summary Semaglutide has one of the most robust clinical trial programmes of any peptide compound. The STEP trial series (for weight management) and SUSTAIN series (for diabetes) collectively enrolled tens of thousands of partici… Tesamorelin has the most extensive human clinical trial dataset of any GHRH analogue, accumulated during its FDA approval programme. Effects on visceral adiposity, metabolic parameters, and cognitive function have been s…
Protocol & Dosing
Typical dose 0.25mg → 2.4mg weekly (weight management)2 mg/day
Frequency Once weeklyOnce daily
Duration Ongoing (chronic management)26–52 weeks (clinical)
Timing Same day each week, any timeBefore breakfast or bedtime
Safety
Common side effects
  • Nausea (44%)
  • Diarrhoea (30%)
  • Vomiting (24%)
  • Constipation (24%)
  • Arthralgia (joint pain)
  • Oedema
  • Myalgia
  • Injection site redness
Contraindications
  • Personal/family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia type 2 (MEN2)
  • Pancreatitis history
  • Active malignancy
  • Pregnancy
  • Hypopituitarism
Anti-doping Not Prohibited Prohibited (WADA S2)
Deeper reading
Related peptides Tirzepatide, AOD-9604, Tesamorelin CJC-1295, Sermorelin, AOD-9604
Full profile Read full Semaglutide profile → Read full Tesamorelin profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.